Covered recipient · General Payments record
PAUL K WINNER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$196,438.99
215 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $151,263.75 | 103 |
| Consulting Fee | $29,171.00 | 14 |
| Honoraria | $11,250.00 | 7 |
| Travel and Lodging | $3,038.68 | 7 |
| Food and Beverage | $1,715.56 | 84 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $68,892.30 | 42 |
| Lilly USA, LLC | $68,400.14 | 73 |
| Allergan, Inc. | $29,982.88 | 37 |
| Lundbeck LLC | $16,512.68 | 19 |
| Amgen Inc. | $12,016.38 | 7 |
| Upsher-Smith Laboratories LLC | $108.56 | 7 |
| Supernus Pharmaceuticals, Inc. | $85.94 | 4 |
| UCB, Inc. | $61.17 | 3 |
| US WorldMeds, LLC | $52.09 | 2 |
| Assertio Therapeutics, Inc. | $43.55 | 2 |
| Biogen, Inc. | $42.27 | 3 |
| EMD Serono, Inc. | $31.08 | 2 |
| Currax Pharmaceuticals LLC | $29.47 | 2 |
| Neurelis, Inc. | $29.45 | 2 |
| SK Life Science, Inc. | $23.94 | 1 |
| Adamas Pharmaceuticals, Inc. | $23.03 | 2 |
| AbbVie Inc. | $17.21 | 1 |
| Mallinckrodt Hospital Products Inc. | $16.59 | 1 |
| Neurocrine Biosciences, Inc. | $16.26 | 1 |
| Kyowa Kirin, Inc. | $14.58 | 1 |
| Bausch Health US, LLC | $14.45 | 1 |
| ACADIA Pharmaceuticals Inc | $13.91 | 1 |
| Novartis Pharmaceuticals Corporation | $11.06 | 1 |
Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PAUL K WINNER
NPI 1831201243 · CMS profile ID 1268856
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology
WEST PALM BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PAUL K WINNER, NPI 1831201243, CMS profile ID 1268856. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). PAUL K WINNER, NPI 1831201243, CMS profile ID 1268856. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- PAUL K WINNER, NPI 1831201243, CMS profile ID 1268856, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 215 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1831201243?year=2020&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
215 matching records · $196,438.99 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 215.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lundbeck LLC | $1,250.00 | 05/28/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580817 | CMS |
| US WorldMeds, LLC | $23.62 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749604499 | CMS |
| Lundbeck LLC | $19.06 | 05/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580815 | CMS |
| Upsher-Smith Laboratories LLC | $12.72 | 05/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 733051045 | CMS |
| Supernus Pharmaceuticals, Inc. | $24.92 | 05/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748371471 | CMS |
| Teva Pharmaceuticals USA, Inc. | $11.94 | 05/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749494285 | CMS |
| Teva Pharmaceuticals USA, Inc. | $2,880.00 | 05/15/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749526535 | CMS |
| Allergan, Inc. | $400.00 | 05/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509343 | CMS |
| Lundbeck LLC | $1,250.00 | 05/05/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580811 | CMS |
| Lundbeck LLC | $1,250.00 | 05/05/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580813 | CMS |
| Teva Pharmaceuticals USA, Inc. | $9,070.00 | 04/29/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749526531 | CMS |
| Teva Pharmaceuticals USA, Inc. | $11.72 | 04/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749458107 | CMS |
| Lundbeck LLC | $2,000.00 | 04/18/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580809 | CMS |
| Teva Pharmaceuticals USA, Inc. | $1,600.00 | 04/03/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749526525 | CMS |
| Lundbeck LLC | $1,000.00 | 04/01/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580807 | CMS |
| Lilly USA, LLC | $950.00 | 03/24/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728581215 | CMS |
| Lilly USA, LLC | $1,068.75 | 03/24/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728588113 | CMS |
| Lilly USA, LLC | $2,612.50 | 03/12/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728591641 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.42 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749497225 | CMS |
| Allergan, Inc. | $2,400.00 | 03/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509339 | CMS |
| Allergan, Inc. | $17.76 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509341 | CMS |
| Lundbeck LLC | $19.58 | 03/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580805 | CMS |
| Lundbeck LLC | $746.79 | 03/06/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580799 | CMS |
| Lundbeck LLC | $398.00 | 03/06/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580801 | CMS |
| Lundbeck LLC | $2,500.00 | 03/06/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747580803 | CMS |
| Teva Pharmaceuticals USA, Inc. | $5,760.00 | 02/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749526505 | CMS |
| Upsher-Smith Laboratories LLC | $18.08 | 02/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 733039895 | CMS |
| Teva Pharmaceuticals USA, Inc. | $466.00 | 02/21/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749517501 | CMS |
| Allergan, Inc. | $11.17 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509333 | CMS |
| Allergan, Inc. | $88.53 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509335 | CMS |
| Allergan, Inc. | $3,000.00 | 02/20/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509337 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.17 | 02/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749454319 | CMS |
| Teva Pharmaceuticals USA, Inc. | $5,040.00 | 02/07/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749526507 | CMS |
| ACADIA Pharmaceuticals Inc | $13.91 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748583583 | CMS |
| Lilly USA, LLC | $431.39 | 02/06/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728578075 | CMS |
| Allergan, Inc. | $2.23 | 02/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509329 | CMS |
| Allergan, Inc. | $2.02 | 02/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509331 | CMS |
| Assertio Therapeutics, Inc. | $22.56 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748831925 | CMS |
| Teva Pharmaceuticals USA, Inc. | $637.20 | 02/04/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749526509 | CMS |
| Supernus Pharmaceuticals, Inc. | $21.36 | 02/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748371467 | CMS |
| Teva Pharmaceuticals USA, Inc. | $121.87 | 02/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749526547 | CMS |
| Allergan, Inc. | $2,400.00 | 01/31/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509325 | CMS |
| Allergan, Inc. | $28.10 | 01/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509327 | CMS |
| Teva Pharmaceuticals USA, Inc. | $12.27 | 01/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749496405 | CMS |
| Allergan, Inc. | $20.35 | 01/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509323 | CMS |
| Allergan, Inc. | $22.40 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509319 | CMS |
| Allergan, Inc. | $2,400.00 | 01/29/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509321 | CMS |
| Allergan, Inc. | $93.28 | 01/25/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509305 | CMS |
| Allergan, Inc. | $3,500.00 | 01/25/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509307 | CMS |
| Allergan, Inc. | $150.92 | 01/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723509309 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,180,569.12 | 226 |
| PY2024 | Recipient | $49,836.22 | 9 |
| PY2024 | Principal investigator | $3,062,085.96 | 126 |
| PY2023 | Recipient | $19,779.76 | 7 |
| PY2023 | Principal investigator | $3,600,760.06 | 86 |
| PY2022 | Recipient | $805.00 | 2 |
| PY2022 | Principal investigator | $2,598,150.72 | 58 |
| PY2021 | Recipient | $995.29 | 2 |
| PY2021 | Principal investigator | $1,254,355.20 | 100 |
| PY2020 | Recipient | $510.84 | 3 |
| PY2020 | Principal investigator | $1,374,402.46 | 113 |
| PY2019 | Recipient | $3,596.00 | 1 |
| PY2019 | Principal investigator | $701,516.02 | 72 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
226 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $300.00 | 12/31/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer s Disease | No dispute reported | 06/30/2026 | 1202534305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,427.00 | 12/29/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399520 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369747 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369749 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $174.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369751 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,767.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369753 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,203.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369755 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,741.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369757 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369759 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $92.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369761 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,203.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369763 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,741.00 | 12/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242369765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,570.00 | 12/22/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399392 |
| Principal investigator 1 | H. Lundbeck A S | $1,300.00 | 12/19/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251778651 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,706.00 | 12/19/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399378 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,300.00 | 12/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399403 |
| Principal investigator 1 | Eisai Inc. | $19,296.00 | 12/17/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560446 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,629.00 | 12/12/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $736.00 | 12/12/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399513 |
| Principal investigator 1 | H. Lundbeck A S | $2,734.00 | 12/01/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251777871 |
| Principal investigator 1 | H. Lundbeck A S | $1,958.00 | 12/01/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251777875 |
| Principal investigator 1 | H. Lundbeck A S | $557.00 | 12/01/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251777878 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,342.00 | 11/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242367847 |
| Principal investigator 1 | Eisai Inc. | $19,606.50 | 11/20/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560448 |
| Principal investigator 1 | GENZYME CORPORATION | $23,604.00 | 11/17/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097781 |
| Principal investigator 1 | GENZYME CORPORATION | $450.00 | 11/17/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097787 |
| Principal investigator 1 | GENZYME CORPORATION | $15,440.00 | 11/17/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097792 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,629.00 | 11/14/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399489 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,000.00 | 11/14/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647462 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $13,850.00 | 11/14/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647468 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,075.00 | 11/13/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399482 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,000.00 | 11/07/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647464 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $13,850.00 | 11/07/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647466 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $118.00 | 11/05/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365727 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $118.00 | 11/05/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365729 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $118.00 | 11/05/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365731 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $118.00 | 11/05/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365733 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,484.00 | 11/03/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399352 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,032.00 | 11/03/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399475 |
| Principal investigator 1 | Novo Nordisk AS | $431.55 | 10/30/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | NN6535-4725 | No dispute reported | 06/30/2026 | 1213729723 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $69,954.59 | 10/27/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190302423 |
| Principal investigator 1 | Eisai Inc. | $13,696.20 | 10/24/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560444 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,342.00 | 10/22/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365017 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,334.00 | 10/22/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365019 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,334.00 | 10/22/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365021 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 10/22/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242365023 |
| Principal investigator 1 | H. Lundbeck A S | $2,734.00 | 10/15/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775665 |
| Principal investigator 1 | H. Lundbeck A S | $557.00 | 10/15/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775668 |
| Principal investigator 1 | H. Lundbeck A S | $2,816.00 | 10/15/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775673 |
| Principal investigator 1 | H. Lundbeck A S | $2,648.00 | 10/15/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251775677 |
| Principal investigator 1 | Eli Lilly and Company | $25.20 | 10/07/2025 | Non-covered Recipient Entity NEUROLOGY RESEARCH INSTITUTE PALM BEACH LLC | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1187885908 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,200.00 | 10/03/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046884 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.00 | 10/03/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046886 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,200.00 | 10/03/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046952 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361709 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,842.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361711 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361713 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,563.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361715 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361717 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,842.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361719 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361721 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,563.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361723 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361725 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,064.00 | 10/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242361727 |
| Principal investigator 1 | GENZYME CORPORATION | $7,440.00 | 09/29/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097701 |
| Principal investigator 1 | GENZYME CORPORATION | $4,800.00 | 09/22/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097689 |
| Principal investigator 1 | Eisai Inc. | $209.91 | 09/17/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560436 |
| Principal investigator 1 | Eisai Inc. | $9,370.80 | 09/17/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560442 |
| Principal investigator 1 | H. Lundbeck A S | $2,816.00 | 09/10/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774559 |
| Principal investigator 1 | H. Lundbeck A S | $557.00 | 09/10/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251774563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 09/05/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399424 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,441.00 | 09/04/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399430 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,538.00 | 09/04/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399537 |
| Principal investigator 1 | GENZYME CORPORATION | $175.00 | 09/03/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097656 |
| Principal investigator 1 | GENZYME CORPORATION | $1,500.00 | 09/03/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097674 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,064.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358132 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358134 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,563.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358136 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,767.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358138 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358140 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,563.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358142 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358144 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,060.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358146 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358148 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $92.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358150 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $236.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358178 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $236.00 | 08/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242358180 |
| Principal investigator 1 | GENZYME CORPORATION | $750.00 | 08/18/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097643 |
| Principal investigator 1 | GENZYME CORPORATION | $1,500.00 | 08/18/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097650 |
| Principal investigator 1 | Janssen Research & Development, LLC | $368.00 | 08/14/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399455 |
| Principal investigator 1 | Eisai Inc. | $17,908.20 | 08/13/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560432 |
| Principal investigator 1 | GENZYME CORPORATION | $29,040.00 | 08/11/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097624 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,145.00 | 08/11/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399471 |
| Principal investigator 1 | H. Lundbeck A S | $2,734.00 | 08/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251773398 |
| Principal investigator 1 | H. Lundbeck A S | $557.00 | 08/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251773403 |
| Principal investigator 1 | H. Lundbeck A S | $2,648.00 | 08/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251773407 |
| Principal investigator 1 | GENZYME CORPORATION | $100.00 | 08/04/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097585 |
| Principal investigator 1 | GENZYME CORPORATION | $8,876.00 | 08/04/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097591 |
| Principal investigator 1 | GENZYME CORPORATION | $5,646.00 | 08/04/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097618 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $354.00 | 08/04/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355744 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $354.00 | 08/04/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355746 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15,000.00 | 08/01/2025 | Non-covered Recipient Entity Premiere Research Institute | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia | No dispute reported | 06/30/2026 | 1235994537 |
| Principal investigator 1 | GENZYME CORPORATION | $4,800.00 | 07/28/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097602 |
| Principal investigator 1 | GENZYME CORPORATION | $150.00 | 07/28/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097607 |
| Principal investigator 1 | GENZYME CORPORATION | $100.00 | 07/28/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097612 |
| Principal investigator 1 | Eisai Inc. | $17,260.20 | 07/23/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560434 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355406 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355408 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355410 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355412 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355414 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,356.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355416 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $824.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355418 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,060.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355420 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,203.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355422 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,741.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355424 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,203.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355426 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,741.00 | 07/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242355428 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 07/21/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399386 |
| Principal investigator 1 | H. Lundbeck A S | $1,482.00 | 07/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772687 |
| Principal investigator 1 | H. Lundbeck A S | $1,550.00 | 07/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772690 |
| Principal investigator 1 | H. Lundbeck A S | $10,500.00 | 07/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772694 |
| Principal investigator 1 | H. Lundbeck A S | $500.00 | 07/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772698 |
| Principal investigator 1 | H. Lundbeck A S | $2,052.00 | 07/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772703 |
| Principal investigator 1 | H. Lundbeck A S | $900.00 | 07/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251772707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,205.00 | 07/11/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399460 |
| Principal investigator 1 | H. Lundbeck A S | $4,068.00 | 07/10/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251772046 |
| Principal investigator 1 | Eisai Inc. | $24,262.20 | 07/09/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560438 |
| Principal investigator 1 | Eisai Inc. | $222.88 | 07/09/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560440 |
| Principal investigator 1 | H. Lundbeck A S | $2,734.00 | 07/09/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251771963 |
| Principal investigator 1 | H. Lundbeck A S | $557.00 | 07/09/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251771967 |
| Principal investigator 1 | H. Lundbeck A S | $2,648.00 | 07/09/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251771971 |
| Principal investigator 1 | GENZYME CORPORATION | $9,440.00 | 07/02/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097572 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $685.03 | 06/24/2025 | Non-covered Recipient Entity Premiere Research Institute At Palm Beach Neurology | Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies | No dispute reported | 06/30/2026 | 1235994533 |
| Principal investigator 1 | Novo Nordisk AS | $4,350.00 | 06/23/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | NN6535-4725 | No dispute reported | 06/30/2026 | 1213756292 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,208.00 | 06/12/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,000.00 | 06/09/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399532 |
| Principal investigator 1 | H. Lundbeck A S | $2,734.00 | 06/06/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251771070 |
| Principal investigator 1 | H. Lundbeck A S | $2,648.00 | 06/06/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | No dispute reported | 06/30/2026 | 1251771074 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,000.00 | 06/03/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE AT PALM BEACH NEUROLOGY | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190300241 |
| Principal investigator 1 | GENZYME CORPORATION | $38,880.00 | 05/19/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097490 |
| Principal investigator 1 | Eli Lilly and Company | $21.49 | 05/16/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1187887996 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $354.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347480 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,104.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347482 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $303.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347484 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $324.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347486 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $354.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347488 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $291.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347490 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,000.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347492 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $850.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347494 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $10,000.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347496 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,616.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347498 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,100.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347500 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,037.00 | 05/16/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | ITI-1284-101 | No dispute reported | 06/30/2026 | 1242347502 |
| Principal investigator 1 | Amgen Inc. | $63,153.30 | 05/15/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis | No dispute reported | 06/30/2026 | 1246646250 |
| Principal investigator 1 | H. Lundbeck A S | $1,855.55 | 05/15/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770250 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,500.00 | 05/13/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE AT PALM BEACH NEUROLOGY | A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy | No dispute reported | 06/30/2026 | 1190300237 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 05/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399362 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 05/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399367 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 05/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399383 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 05/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399451 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 05/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 05/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399526 |
| Principal investigator 1 | GENZYME CORPORATION | $5,000.00 | 05/05/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,168.00 | 05/05/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399508 |
| Principal investigator 1 | Janssen Research & Development, LLC | $871.00 | 05/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399411 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,502.00 | 05/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399417 |
| Principal investigator 1 | Janssen Research & Development, LLC | $871.00 | 05/02/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399465 |
| Principal investigator 1 | GENZYME CORPORATION | $300.00 | 04/28/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097463 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $968.50 | 04/28/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046882 |
| Principal investigator 1 | GENZYME CORPORATION | $8,464.00 | 04/21/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097469 |
| Principal investigator 1 | Eli Lilly and Company | $1.68 | 04/16/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187887564 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.00 | 04/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046876 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,200.00 | 04/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046878 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $173.71 | 04/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046880 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,200.00 | 04/08/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244046950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,121.00 | 04/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399342 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,149.00 | 04/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399485 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,823.00 | 04/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399542 |
| Principal investigator 1 | PFIZER INC. | $4,500.00 | 04/04/2025 | Non-covered Recipient Entity Palm Beach Neurology | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228777557 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $37,054.74 | 03/31/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190310470 |
| Principal investigator 1 | Eli Lilly and Company | $4,535.10 | 03/25/2025 | Non-covered Recipient Entity ATLANTA CENTER FOR MEDICAL RESEARCH | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187875987 |
| Principal investigator 1 | H. Lundbeck A S | $2,652.85 | 03/25/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769056 |
| Principal investigator 1 | GENZYME CORPORATION | $5,125.00 | 03/24/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097358 |
| Principal investigator 1 | Janssen Research & Development, LLC | $71,544.00 | 03/24/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399348 |
| Principal investigator 1 | Eisai Inc. | $32,067.90 | 03/21/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560428 |
| Principal investigator 1 | GENZYME CORPORATION | $17,828.00 | 03/17/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097191 |
| Principal investigator 1 | ABBVIE INC. | $2,175.00 | 03/13/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 1202463005 |
| Principal investigator 1 | Eli Lilly and Company | $12,839.92 | 03/10/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187889172 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,621.00 | 03/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399358 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,029.00 | 03/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399398 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,502.00 | 03/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399434 |
| Principal investigator 1 | GENZYME CORPORATION | $19,200.00 | 03/04/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097395 |
| Principal investigator 1 | H. Lundbeck A S | $3,578.50 | 03/04/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251768073 |
| Principal investigator 1 | Eli Lilly and Company | $1,845.50 | 02/25/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187890034 |
| Principal investigator 1 | GENZYME CORPORATION | $16,264.00 | 02/18/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097184 |
| Principal investigator 1 | GENZYME CORPORATION | $75.00 | 02/18/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097376 |
| Principal investigator 1 | H. Lundbeck A S | $1,855.55 | 02/18/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251767437 |
| Principal investigator 1 | Eli Lilly and Company | $24.15 | 02/07/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187888150 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,583.00 | 02/06/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399445 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $94,425.92 | 02/05/2025 | Non-covered Recipient Entity Premiere Research Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) | No dispute reported | 06/30/2026 | 1235994535 |
| Principal investigator 1 | H. Lundbeck A S | $4,068.00 | 02/05/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251767018 |
| Principal investigator 1 | Eli Lilly and Company | $4,395.20 | 01/31/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187888700 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $45,571.02 | 01/31/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190307091 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,207,680.85 | 01/29/2025 | Non-covered Recipient Entity Premiere Research Institute At Palm Beach Neurology | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235994531 |
| Principal investigator 1 | H. Lundbeck A S | $4,529.65 | 01/29/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766759 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,335.88 | 01/28/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE AT PALM BEACH NEUROLOGY | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190300239 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,491.58 | 01/27/2025 | Non-covered Recipient Entity Premiere Research Institute At Palm Beach Neurology | A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) | No dispute reported | 06/30/2026 | 1235994529 |
| Principal investigator 1 | Eli Lilly and Company | $13,635.26 | 01/27/2025 | Non-covered Recipient Entity ATLANTA CENTER FOR MEDICAL RESEARCH | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187875015 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,848.00 | 01/24/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease | No dispute reported | 06/30/2026 | 1175399439 |
| Principal investigator 1 | Eisai Inc. | $18,351.90 | 01/23/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560426 |
| Principal investigator 1 | Eisai Inc. | $22,306.50 | 01/23/2025 | Non-covered Recipient Entity Premiere Research Institute at Palm Beach Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | No dispute reported | 06/30/2026 | 1244560430 |
| Principal investigator 1 | Eli Lilly and Company | $361,755.55 | 01/22/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187887958 |
| Principal investigator 1 | Eli Lilly and Company | $1,149,126.19 | 01/21/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1187887562 |
| Principal investigator 1 | GENZYME CORPORATION | $37,704.00 | 01/13/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097363 |
| Principal investigator 1 | GENZYME CORPORATION | $17,616.00 | 01/13/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097370 |
| Principal investigator 1 | GENZYME CORPORATION | $15,410.00 | 01/13/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097381 |
| Principal investigator 1 | GENZYME CORPORATION | $18,616.00 | 01/13/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097386 |
| Principal investigator 1 | GENZYME CORPORATION | $1,882.00 | 01/13/2025 | Non-covered Recipient Entity Palm Beach Neurology Premiere Research Institute | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226097390 |
| Principal investigator 1 | Amgen Inc. | $160.00 | 01/12/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis | No dispute reported | 06/30/2026 | 1246646754 |
| Principal investigator 1 | PFIZER INC. | $4,500.00 | 01/09/2025 | Non-covered Recipient Entity Palm Beach Neurology | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228765596 |
| Principal investigator 1 | H. Lundbeck A S | $2,652.85 | 01/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766265 |
| Principal investigator 1 | H. Lundbeck A S | $9,666.20 | 01/07/2025 | Non-covered Recipient Entity PALM BEACH NEUROLOGY | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766269 |
| Principal investigator 1 | Eli Lilly and Company | $551,361.69 | 01/06/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187887566 |
| Principal investigator 1 | Eli Lilly and Company | $230,180.83 | 01/06/2025 | Non-covered Recipient Entity PREMIER RESEARCH INSTITUTE | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187889174 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $214,925.35 | 01/01/2025 | Non-covered Recipient Entity PREMIERE RESEARCH INSTITUTE | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190302839 |